SAKAR2024-04-012024-06-30 SAKAR2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SAKAR2024-06-30 SAKAR2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 123456 SAKAR NOTLISTED Sakar Healthcare Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-08 INR Lakhs First quarter 11:30:00 12:00:00 2024-08-13 2024-08-13 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 411477000.00 4598000.00 416075000.00 224970000.00 0.00 -4356000.00 53845000.00 13981000.00 50575000.00 30029000.00 369044000.00 47031000.00 0.00 47031000.00 0.00 22911000.00 22911000.00 0.00 24120000.00 0.00 0.00 0.00 0.00 24120000.00 -267000.00 23853000.00 0.00 0.00 217499000.00 10 1.10 1.09 0.00 0.00 1.10 1.09 1. The Company is operating only in one segment. Hence segment reporting is not given. 2. The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited. 3. The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. 4. Provision for taxation/deferred taxation, if any, will be made at the year end. 5. Figures, wherever required, are regrouped / rearranged. 6. The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgments and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, based on the information available to date, while preparing the Company’s financial results as of and for the quarter ended 30th June, 2024 7. The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 13th August, 2024 Other expenses 30029000.00 Re-measurement gains/(losses) on defined benefit plans -370000.00 -370000.00 -103000.00 0.00